FDA clears Biosite's Triage TOX drug screen:
This article was originally published in Clinica
Executive Summary
Biosite has received US FDA 510(k) clearance to market its point-of-care Triage TOX drug screen, a qualitative test that enables hospital physicians to test for eight classes of commonly abused drugs in urine in around 15 minutes. The test is run on the San Diego, California firm's Triage MeterPlus, a small, portable instrument that also serves as a testing platform for Biosite's tests for cardiovascular disease, such as heart attack and congestive heart failure.